These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33508377)

  • 1. Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    Javitt NB
    J Hepatol; 2021 May; 74(5):1267. PubMed ID: 33508377
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    Keiding S; Frisch K; Hofmann AF
    J Hepatol; 2021 May; 74(5):1268-1269. PubMed ID: 33621633
    [No Abstract]   [Full Text] [Related]  

  • 3. Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.
    Hvas CL; Ott P; Paine P; Lal S; Jørgensen SP; Dahlerup JF
    World J Gastroenterol; 2018 Jun; 24(21):2320-2326. PubMed ID: 29881241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
    Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
    Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 7. The protective effect of obeticholic acid on lipopolysaccharide-induced disorder of maternal bile acid metabolism in pregnant mice.
    Zhang C; Gan Y; Lv JW; Qin MQ; Hu WR; Liu ZB; Ma L; Song BD; Li J; Jiang WY; Wang JQ; Wang H; Xu DX
    Int Immunopharmacol; 2020 Jun; 83():106442. PubMed ID: 32248018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: long-term treatment of severe bile acid diarrhoea-obeticholic acid can normalise SeHCAT retention.
    Walters JRF
    Aliment Pharmacol Ther; 2018 Nov; 48(9):1032-1034. PubMed ID: 30318683
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: long-term treatment of severe bile acid diarrhoea-obeticholic acid can normalise SeHCAT retention. Authors' reply.
    Damsgaard B; Dalby HR; Krogh K; Jørgensen SMD; Arveschough AK; Agnholt J; Dahlerup JF; Jørgensen SP
    Aliment Pharmacol Ther; 2018 Nov; 48(9):1034-1035. PubMed ID: 30318688
    [No Abstract]   [Full Text] [Related]  

  • 10. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis.
    Roda A; Aldini R; Camborata C; Spinozzi S; Franco P; Cont M; D'Errico A; Vasuri F; Degiovanni A; Maroni L; Adorini L
    Clin Transl Sci; 2017 Jul; 10(4):292-301. PubMed ID: 28411380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acids: emerging role in management of liver diseases.
    Asgharpour A; Kumar D; Sanyal A
    Hepatol Int; 2015 Oct; 9(4):527-33. PubMed ID: 26320013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
    de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
    [No Abstract]   [Full Text] [Related]  

  • 14. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
    Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
    J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of obeticholic acid in brown bullhead (Ameiurus nebulosus).
    Mach S; Jegorov A; Šimek Z
    Environ Sci Pollut Res Int; 2019 Jul; 26(20):20316-20324. PubMed ID: 31093919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile acid metabolism in cirrhotic liver tissue--altered synthesis and impaired hepatic secretion.
    Akashi Y; Miyazaki H; Yanagisawa J; Nakayama F
    Clin Chim Acta; 1987 Sep; 168(2):199-206. PubMed ID: 3677416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X receptor and bile acids regulate vitamin A storage.
    Saeed A; Yang J; Heegsma J; Groen AK; van Mil SWC; Paulusma CC; Zhou L; Wang B; Faber KN
    Sci Rep; 2019 Dec; 9(1):19493. PubMed ID: 31862954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
    Friedman ES; Li Y; Shen TD; Jiang J; Chau L; Adorini L; Babakhani F; Edwards J; Shapiro D; Zhao C; Carr RM; Bittinger K; Li H; Wu GD
    Gastroenterology; 2018 Dec; 155(6):1741-1752.e5. PubMed ID: 30144429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
    Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
    Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portal venous bile acids in cholesterol gallstone disease: effect of treatment with chenodeoxycholic and cholic acids.
    Einarsson K; Ahlberg J; Angelin B; Björkhem I; Ewerth S
    Hepatology; 1985; 5(4):661-5. PubMed ID: 4018738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.